Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

First Posted Date
2021-08-18
Last Posted Date
2024-07-11
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Target Recruit Count
17
Registration Number
NCT05009953
Locations
🇨🇳

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

First Posted Date
2021-07-02
Last Posted Date
2024-12-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
862
Registration Number
NCT04949256
Locations
🇨🇷

PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica

🇨🇳

Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China

🇨🇳

West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China

and more 192 locations

Perioperative Chemotherapy in Gastric Cancer

First Posted Date
2021-06-24
Last Posted Date
2024-11-06
Lead Sponsor
Ukrainian Society of Clinical Oncology
Target Recruit Count
69
Registration Number
NCT04937738
Locations
🇺🇦

National Cancer Institute, Kyiv, Ukraine

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

First Posted Date
2021-05-11
Last Posted Date
2024-10-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT04882241
Locations
🇨🇳

Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638), Bengbu, Anhui, China

🇨🇳

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647), Xi'an, Shaanxi, China

🇨🇳

Beijing Friendship Hospital ( Site 0637), Beijing, Beijing, China

and more 17 locations

No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer

First Posted Date
2021-04-28
Last Posted Date
2023-11-22
Lead Sponsor
Servicio de Salud Metropolitano Sur Oriente
Target Recruit Count
73
Registration Number
NCT04864067
Locations
🇨🇱

Complejo Asistencial Doctor Sótero del Rio, Santiago, RM, Chile

🇨🇱

Hospital Padre Hurtado, Santiago, RM, Chile

🇨🇱

Hospital La Florida, Santiago, RM, Chile

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

First Posted Date
2021-02-21
Last Posted Date
2023-12-22
Lead Sponsor
University of California, Irvine
Target Recruit Count
35
Registration Number
NCT04762953
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

First Posted Date
2021-02-12
Last Posted Date
2023-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
17
Registration Number
NCT04752163
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2021-02-12
Last Posted Date
2024-11-20
Lead Sponsor
Cardiff Oncology
Target Recruit Count
43
Registration Number
NCT04752696
Locations
🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 3 locations

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

First Posted Date
2021-01-11
Last Posted Date
2024-01-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
25
Registration Number
NCT04703101
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

First Posted Date
2020-12-30
Last Posted Date
2022-04-04
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
18
Registration Number
NCT04689347
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy